DOCSLIB.ORG

The Francis Crick Institute

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Francis Crick Institute 7/13/2017 Knighthood for Dr Richard Treisman | The Francis Crick Institute TheT hFrancisis site uses c oCrickokies to improve yoHOMEur expeABOUTrience. USBy coRESEARCHntinuing to usOURe thi sBUILDING site, you areSTRATEGY agreeing to tWHAT'Sheir use .ON MoreNEWS about CCONTACTookies C USontinue Institute Home / News / News archive / 2016 / 06 / 11 / Knighthood for Dr Richard Treisman Knighthood for Dr Richard Treisman 11 June 2016 Dr Richard Treisman, Research Director at the Francis Crick Institute, has been knighted in the Queen's Birthday Honours for services to biomedical science and to cancer research. News archive Richard became Director of 2017 Laboratory Research at the Imperial Cancer Research Fund 2016 in 1999, and Director of the Cancer Research UK London 2015 Research Institute upon the foundation of CRUK in 2002. 2014 Dr Richard Treisman, biochemist, molecular biologist and 2013 Research Director at the Francis Crick Institute, has been knighted in the Queen's Birthday Honours for services to 2012 biomedical science and to cancer research. LINKS 2011 Internal 2010 Richard's research seeks to understand at the molecular level how chemical signals arriving at a cell's surface are transmitted to the Richard Treisman research laboratory 2009 cell nucleus to alter the expression of specific genes. 2008 External His main focus is on a system known as the SRF network, which Science news Cancer Research UK regulates expression both of genes important for cell CrickNews proliferation, and for cell movement and adhesion, functions critical for cancer cell growth and spread. Press releases Publications Richard Treisman received his PhD in 1981, for work on virus gene expression with Bob Kamen at the former Imperial Cancer Sitemap Research fund. Following postdoctoral work in the USA with Tom Cookies Maniatis, he joined the staff of the Medical Research Council Privacy Laboratory for Molecular Biology in Cambridge in 1984, where he Accessibility started working on how gene transcription is regulated by growth Terms and conditions factors. He continued this work after he returned to the ICRF in 1988. A major current research interest is in how changes in the Follow the Crick activity of the cell's dynamic internal framework ‐ the 'cytoskeleton' ‐ are transformed into changes in gene expression. Richard became Director of Laboratory Research at the Imperial Cancer Research Fund in 1999, and Director of the Cancer Research UK London Research Institute upon the foundation of CRUK in 2002. He is currently a Research Director at the Francis Crick Institute. Richard is member of EMBO, a Fellow of the Royal Society and a Fellow of the Academy of Medical Sciences. He was awarded the EMBO medal in 1995 and the Jeantet Prize for Medicine in 2002. Sir Paul Nurse, Director of the Francis Crick institute, said: "I am absolutely delighted that Richard's world‐leading contributions have been recognised with a knighthood. Having worked with him over many years I greatly respect both his research and his leadership. I speak for all our colleagues at the Crick in congratulating him for this well‐deserved honour." Sir Harpal Kumar, Cancer Research UK's chief executive, said: "This is wonderful news and fantastic recognition for Richard's work. He has spent his career working to better understand the complexity of cancer, and how our cells regulate DNA and coordinate gene activity. He has also been instrumental in identifying and mentoring outstanding young scientists who have gone on to become world leaders in their fields. https://www.crick.ac.uk/news/news-archive/2016/06/11/knighthood-for-dr-richard-treisman/ 1/2 7/13/2017 Knighthood for Dr Richard Treisman | The Francis Crick Institute "In 2000 Richard became director of the Cancer Research UK This site uses cookies to improveL yoonudr oenx pReeriseenacrec. hB yIn csotnituintuein, ga tnod u usen dtheirs hsiitse ,l eyoadu earrseh aipgr etheien gIn tsot itthuetire use. More about Cookies Continue became a powerhouse of ground‐breaking research that grew in reputation across the world. "The charity is very lucky to have been able to support so much of his work, since the early days of his PhD when we were the Imperial Cancer Research Fund, and with his ongoing role as a research director at the Francis Crick Institute, we look forward to many more years of working together. It's only through work such as Richard's that we're able to develop discovering new ways to prevent, diagnose and treat cancer. This is thoroughly deserved and I'm delighted for Richard." Richard said: "This is a wonderful honour, one which reflects the efforts of the many talented people who have worked with me, and the outstanding research organisations that have supported my research over the years." The Francis Crick Institute is a unique partnership between the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King's College London. The Francis Crick Institute Limited is a registered charity in England and Wales no. 1140062 and a company registered in England and Wales no. 06885462, with its registered office at 1 Midland Road, London NW1 1AT. https://www.crick.ac.uk/news/news-archive/2016/06/11/knighthood-for-dr-richard-treisman/ 2/2.
Load more

Recommended publications
  • New Editor on Journal of Cell Science Michael Way (Editor-In-Chief)
    © 2019. Published by The Company of Biologists Ltd | Journal of Cell Science (2019) 132, jcs229740. doi:10.1242/jcs.229740 EDITORIAL New Editor on Journal of Cell Science Michael Way (Editor-in-Chief) As someone who has worked on things related to the actin cytoskeleton my whole research career, the nucleus was not something I paid much attention to. Yes, there were scattered historical reports of actin in the nucleus long before I started my PhD, but no one believed actin was really there of course – it was all an artefact of fixation, you know. Nuclear actin was taboo and no one talked about it at the meetings I went to as a student and postdoc. How wrong we were – today nuclear actin is alive and kicking, although there are definitely more questions than answers concerning what it is actually doing there. We now appreciate that the nucleus contains a wide assortment of proteins associated with the cytoplasmic actin cytoskeleton including myosin motors and actin nucleators such as the Arp2/3 complex. In addition, it should not be forgotten that many chromatin-associated complexes including SWI/SNF and INO80/ SWR also contain multiple actin-related proteins, as well as actin itself. It strikes me that maybe we should all be paying more attention to the nucleus and not just because it contains my favourite proteins! Maybe that’s why, in recent years, we’ve been seeing more submissions to JCS that are focused on different aspects of the nucleus and that traditionally appeared in journals with ‘molecular’ in their titles.
    [Show full text]
  • Transcriptional Regulation by Extracellular Signals 209
    Cell, Vol. 80, 199-211, January 27, 1995, Copyright © 1995 by Cell Press Transcriptional Regulation Review by Extracellular Signals: Mechanisms and Specificity Caroline S. Hill and Richard Treisman Nuclear Translocation Transcription Laboratory In principle, regulated nuclear localization of transcription Imperial Cancer Research Fund factors can involve regulated activity of either nuclear lo- Lincoln's Inn Fields calization signals (NLSs) or cytoplasmic retention signals, London WC2A 3PX although no well-characterized case of the latter has yet England been reported. N LS activity, which is generally dependent on short regions of basic amino acids, can be regulated either by masking mechanisms or by phosphorylations Changes in cell behavior induced by extracellular signal- within the NLS itself (Hunter and Karin, 1992). For exam- ing molecules such as growth factors and cytokines re- ple, association with an inhibitory subunit masks the NLS quire execution of a complex program of transcriptional of NF-KB and its relatives (Figure 1; for review see Beg events. While the route followed by the intracellular signal and Baldwin, 1993), while an intramolecular mechanism from the cell membrane to its transcription factor targets may mask NLS activity in the heat shock regulatory factor can be traced in an increasing number of cases, how the HSF2 (Sheldon and Kingston, 1993). When transcription specificity of the transcriptional response of the cell to factor localization is dependent on regulated NLS activity, different stimuli is determined is much less clear. How- linkage to a constitutively acting NLS may be sufficient to ever, it is possible to understand at least in principle how render nuclear localization independent of signaling (Beg different stimuli can activate the same signal pathway yet et al., 1992).
    [Show full text]
  • Written Evidence UK Centre for Medical
    Science & Technology Committee: Written evidence UK Centre for Medical Research & Innovation (UKCMRI) This volume contains the written evidence accepted by the Science & Technology Committee for the UK Centre for Medical Research & Innovation (UKCMRI) inquiry. UKCMRI Author UKCMRI Author 00 BIS 17 Camden Green Party 01 Faculty of Pharmaceutical Medicine 18 Councillor Roger Robinson, St Pancras and Somers Town Ward 02 The Academy of Medical Sciences 20 John Mason 03 Director, Medical Research Council 21 T Morgan National Institute for Medical Research 04 UKCMRI Limited 22 Frankie Biney 04a Supplementary 04b Further supplementary 04c Further supplementary 05 Robert Henderson 23 Rt. Hon. Frank Dobson MP 05a Supplementary 06 Medical Research Council’s National Trade Union Side 07 Mireille Burton 08 King’s College London 09 Joint submission: Cancer Research UK, MRC, UCL, and Wellcome Trust 09a Supplementary (MRC) 09b Further supplementary (MRC) 10 Isabel Vasseur 11 St Pancras and Somers Town Planning Action 11a Supplementary 12 Imperial College London 13 The Public & Commercial Services Union 14 Action for our Planet 15 GlaxoSmithKline R&D 16 Professor G G Dodson 16a Supplementary 16b Further supplementary As at 20 April 2011 Written evidence submitted by the Department for Business, Innovation & Skills (BIS) (UKCMRI 00) The UK Centre for Medical Research and Innovation (UKCMRI) will be a world-class centre for biomedical research, located in the London Borough of Camden. UKCMRI will be an independent institute funded by the Medical Research Council, Cancer Research UK, the Wellcome Trust and University College London. The funding partners, and separately UKCMRI, will also be submitting a memorandum to the Select Committee.
    [Show full text]
  • The Role of WH2-Containing Proteins in Regulating Actin-MRTF-SRF-Mediated Transcription
    The Role of WH2-containing Proteins in Regulating Actin-MRTF-SRF-mediated Transcription Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) der Naturwissenschaftlichen Fakultät I – Biowissenschaften - der Martin-Luther-Universität Halle-Wittenberg vorgelegt von Frau Julia Weißbach geboren am 24.06.1987 in Querfurt Gutachter: Prof. Guido Posern Prof. Mechthild Hatzfeld Prof. Bernd Knöll Verteidigungsdatum: 15. November 2017 Content I Summary ...................................................................................................................... 3 Zusammenfassung ....................................................................................................... 4 II Introduction ............................................................................................................... 5 II.1 Serum Response Factor - SRF ............................................................................... 5 II.2 Myocardin-related Transcription Factors – MRTF-A/-B ...................................... 6 II.3 Actin and Actin-Binding Proteins .......................................................................... 9 II.4 Nucleation Promoting Factors – NPF .................................................................. 12 II.4.1 Neuronal Wiskott-Aldrich Syndrome Protein – N-WASP ........................... 14 II.4.2 WASP Family Verprolin-homologous Protein 2 - WAVE2 ......................... 15 II.4.3 Junction-mediating and Regulatory Protein - JMY ...................................... 15
    [Show full text]
  • Commercial Partnerships Annual Review 19/20
    1 Overview Commercial Partnerships Annual Review 19/20 Together we will beat cancer 2 Overview Our missions & values Contents CRUK’s vision is to bring forward the day when all cancers Overview are cured. Over the last 40 years, cancer survival rates in 4 CBO’s statement the UK have doubled. In the 1970s just a quarter of people 5 Highlights from the 19/20 financial year survived. Today that figure is half. In order to improve on this, we need to work with industry partners to progress Introduction the best ideas to market. This is where the Commercial Partnerships team can help. 2 What we do and why 7 Where we do it 8 Our principles for doing business 9 Our commitment to CRUK funded researchers Our Our Our 10 Our Commercial Objectives mission vision ambition Our achievements 11 - 17 Objective 1: Supporting researchers with translational activity The mission of CRUK Commercial Together we will 18 - 19 Objective 2: Encouraging entrepreneurial culture and skills in CRUK Commercial Partnerships will be beat cancer and our research community Partnerships is to the world’s leading see 3/4 of people maximise the translation cancer translation and survive by 2034 20 - 26 Objective 3: Develop industry partnerships in therapeutics of cancer research for commercialisation 27 - 29 Objective 4: Diversify and maximise opportunities beyond therapeutics patient benefit group 30 - 31 Objective 5: Invest in our people and processes, promote diversity See our objectives on See our achievements on See our impact on 32 - 35 Objective 6: Leverage and return
    [Show full text]
  • TGF-B Uses a Novel Mode of Receptor Activation to Phosphorylate SMAD1
    RESEARCH ARTICLE TGF-b uses a novel mode of receptor activation to phosphorylate SMAD1/5 and induce epithelial-to-mesenchymal transition Anassuya Ramachandran1, Pedro Viza´ n1†, Debipriya Das1‡, Probir Chakravarty2, Janis Vogt3, Katherine W Rogers4, Patrick Mu¨ ller4, Andrew P Hinck5, Gopal P Sapkota3, Caroline S Hill1* 1Developmental Signalling Laboratory, The Francis Crick Institute, London, United Kingdom; 2Bioinformatics and Biostatistics Facility, The Francis Crick Institute, London, United Kingdom; 3Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, United Kingdom; 4Friedrich Miescher Laboratory of the Max Planck Society, Tu¨ bingen, Germany; 5Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States Abstract The best characterized signaling pathway downstream of transforming growth factor b (TGF-b) is through SMAD2 and SMAD3. However, TGF-b also induces phosphorylation of SMAD1 *For correspondence: and SMAD5, but the mechanism of this phosphorylation and its functional relevance is not known. [email protected] Here, we show that TGF-b-induced SMAD1/5 phosphorylation requires members of two classes of type I receptor, TGFBR1 and ACVR1, and establish a new paradigm for receptor activation where Present address: †Center for TGFBR1 phosphorylates and activates ACVR1, which phosphorylates SMAD1/5. We demonstrate Genomic Regulation, Barcelona, ‡ the biological significance of this pathway by showing that approximately a quarter of the TGF-b- Spain; Flow Cytometry, The Francis Crick Institute, London, induced transcriptome depends on SMAD1/5 signaling, with major early transcriptional targets ID United Kingdom being the genes. Finally, we show that TGF-b-induced epithelial-to-mesenchymal transition requires signaling via both the SMAD3 and SMAD1/5 pathways, with SMAD1/5 signaling being Competing interests: The essential to induce ID1.
    [Show full text]
  • [email protected] FST Journal Publishes Summaries of All the Talks Given at Its Meetings
    journal The Journal of The Foundation for Science and Technology fstVolume 22 Number 2 March 2018 www.foundation.org.uk Editorial Sir David Cannadine: The role of the Academies in providing independent advice to Government An industrial strategy for the UK Lord Hennessy: Searching for a strategy that makes a difference Lord Heseltine: Establishing a strategy for the whole economy Lord Willetts: A tension at the heart of Government activity A business strategy for Scotland Professor Iain Gray: Translating research excellence into economic benefit Nora Senior: Plugging gaps in performance Dame Susan Rice: An ecosystem for business Paul Wheelhouse: Driving innovation Meeting air quality targets Dr Stephen Bryce: The energy emissions challenge Professor Frank Kelly: The health consequences of air pollution Diagnosing cancer earlier Sir Harpal Kumar: Early diagnosis has the potential to transform patient outcomes Dr Clare Turnbull: Using genetics to combat cancer The rise of machine learning Dr Mike Lynch: An opportunity or a threat to society? Dr Claire Craig: Giving society the confidence to embrace opportunities Amir Saffari: The potential to augment human efforts Dame Wendy Hall: The opportunities for the UK Comment Norman Lamb: The future of social care Obituary The Rt Hon Sir Brian Neill COUNCIL AND TRUSTEES COUNCIL CHIEF EXECUTIVE Chair Dr Dougal Goodman OBE FREng The Earl of Selborne* GBE FRS Deputy Chairs The Baroness O’Neill of Bengarve* CH CBE FBA FRS FMedSci Dr Mike Lynch* OBE FRS FREng DL President, The Royal Society Professor
    [Show full text]
  • The Francis Crick Institute
    Clinical Medicine 2017 Vol 17, No 2: 105–7 PROFESSIONAL ISSUES T h e F r a n c i s C r i c k I n s t i t u t e A u t h o r s : K e i t h P e t e r s A a n d J i m S m i t h B The Francis Crick Institute Laboratory, opened in 2016, is sup- is within easy reach of GlaxoSmithKine (GSK) and Astra ported by the Medical Research Council, Cancer Research UK, Zeneca’s principal research laboratories in Stevenage and the Wellcome Trust, and University College London, King’s Col- Cambridge, respectively. lege London and Imperial College London. The emphasis on But in order to justify investment on the scale required, the research training and early independence of gifted scientists new institute needed to be more than a simple translocation to ABSTRACT in a multidisciplinary environment provides unique opportuni- a new site. ties for UK medical science, including clinical and translational After discussion and negotiation, the MRC, Cancer Research research. UK (CRUK), the Wellcome Trust and University College London (UCL) created a partnership: CRUK’s London Research K E Y W O R D S : MRC , CRUK , Wellcome , Crick , UCL , King’s , Imperial Institute (LRI) would join the NIMR, with researchers from UCL contributing expertise in the physical and clinical sciences. Importantly, the Crick was not simply to be a merger The Francis Crick Institute has been referred to as the most of LRI and NIMR but a new entity with a different ethos – a significant development in UK biomedical science for a multidisciplinary institute with a substantial new investment in generation.
    [Show full text]
  • Cancer Research UK Submission to the European Commission Assessment of The
    Cancer Research UK submission to the European Commission assessment of the January 2010 About Cancer Research UK Cancer Research UK (CR-UK)1 is leading the world in finding new ways to prevent, diagnose and independent funder of cancer research in Europe. Over half of all cancer research in the UK is carried out by our doctors and scientists. Cancer Re s entirely funded by the public and in 2008/09 we spent £355 million on research, supporting the work of more than 4,500 scientists, doctors and nurses. CR-UK funds research into all aspects of cancer from exploratory biology to clinical trials of novel and existing drugs as well as population-based studies and prevention research. Our scientists, doctors and nurses have contributed to the development of 19 of the top 20 drugs used to treat cancer patients worldwide today. At CR-UK we are involved with all stages of clinical trials, and we have a perspective both as a funder of academics conducting trials and as a Sponsor of early phase trials. For further information about our involvement in clinical trials, please see appendix 1. For further information about the implementation of the Clinical Trials Directive (CTD) in the UK, please see appendix 2. For a glossary of terms used throughout this response, please see appendix 3. Acknowledgements Our response has been collated following internal staff discussion and with contributions from the follow additional groups/individuals: Cancer Research UK Clinical Trials Unit, University of Birmingham Charles Coombes, Director, Department of Oncology,
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • April 28 Sir Paul Nurse
    MONDAY, APRIL 26th 8 pm We look forward to welcoming to Kenton SIR PAUL NURSE RATHER THAN GIVE A TALK, WE ARE VERY FORTUNATE IN THAT SIR PAUL IS HAPPY TO ANSWER QUESTIONS ON HIS EXTENSIVE CAREER AND HOBBIES PLEASE HAVE YOUR QUESTIONS READY OR SEND THEM IN BEFORE THE MEETING Paul Nurse is a geneticist and cell biologist who has worked on how the eukaryotic cell cycle is controlled. His major work has been on the cyclin dependent protein kinases and how they regulate cell reproduction. He is Director of the Francis Crick Institute in London, and has served as President of the Royal Society, Chief Executive of Cancer Research UK and President of Rockefeller University. He shared the 2001 Nobel Prize in Physiology or Medicine and has received the Albert Lasker Award, the Gairdner Award, the Louis Jeantet Prize and the Royal Society's Royal and Copley Medals. He was knighted by The Queen in 1999, received the Legion d'honneur in 2003 from France, and the Order of the Rising Sun in 2018 from Japan. He served for 15 years on the Council of Science and Technology, advising the Prime Minister and Cabinet, and is presently a Chief Scientific Advisor for the European Union. As well as his many medical accomplishments, amazingly Paul also has time to fly planes and engage in varied hobbies Paul flies gliders and vintage aeroplanes and has been a qualified bush pilot. He also likes the theatre, hill-walking, going to museums and art galleries, and running very slowly. All our Zoom sessions are available on the Kenton https://us02web.zoom.us/j/3531782577? YouTube channel: pwd=N0tlSWxxUGZmOEUrM1ZzclJFN1pzdz09 Kenton Shul In The Park Goes Live.
    [Show full text]
  • UKRI Explainer
    UK Research and Innovation (UKRI) What is UKRI? UK Research and Innovation (UKRI) was established by the UKRI delivers the majority of public funding for research Higher Education and Research Act 2017 and was launched and innovation in the UK. It will play a central role in in April 2018. The purpose of UKRI is to create a strong, realising the UK Government’s ambition of 2.4% of gross agile and joined up funder of research and innovation for domestic product (GDP) investment in research and the UK. UKRI brings together the seven Research Councils, development (R&D) by 2027. This explainer summarises Innovate UK and Research England (formally the Higher UKRI’s structure, governance and operation to support Education Funding Council for England (HEFCE)). UKRI and discussion over how this funding is distributed. its constituent Councils published their first Delivery Plans in June 20191. FIGURE 1 Who makes up UKRI? UK Research and Innovation (UKRI) Engineering UKRI is made up of nine Councils: seven Research Councils, Innovate UK Economic and Physical and Social and Research England. Sciences Research Research Council Research Councils Council (ESRC) (EPSRC) The seven Research Councils, divided by scientific discipline, support Biotechnology and Biological Medical excellent research by providing grant funding, access to excellent research Sciences Research facilities and investing in infrastructure and institutions. Research Council Council (MRC) Innovate UK (BBSRC) The UK’s innovation agency, works with companies to de-risk, enable and support innovation, including through providing innovation grants and UK Research and Science and Arts and investing in Catapult centres. Technology Innovation (UKRI) Humanities Facilities Research Research England Council Council Research England supports English Higher Education providers to (STFC) (AHRC) deliver funding for research and knowledge exchange formerly performed by HEFCE.
    [Show full text]